# Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 Balance Sheet

- Company: Kiniksa Pharmaceuticals International, plc (KNSA)
- Period: As of 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-27, accession number 0001104659-26-119186
- Page: https://plicit.ai/financials/knsa/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/knsa-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 983,243,000 US dollars
- **Current assets**: 750,099,000 US dollars
- **Non-current assets**: 233,144,000 US dollars
- **Liabilities**: 273,050,000 US dollars
- **Current liabilities**: 191,855,000 US dollars
- **Non-current liabilities**: 81,195,000 US dollars
- **Equity**: 710,193,000 US dollars
- **Short-term investments**: 487,098,000 US dollars
- **Inventory**: 108,028,000 US dollars
- **Cash and cash equivalents**: 81,660,000 US dollars
- **Prepaid expenses and other current assets**: 42,534,000 US dollars
- **Accounts receivable, net**: 30,779,000 US dollars
- **Deferred tax assets**: 198,042,000 US dollars
- **Intangible asset, net**: 14,500,000 US dollars
- **Other long-term assets**: 10,749,000 US dollars
- **Operating lease right-of-use assets**: 7,389,000 US dollars
- **Property and equipment, net**: 2,464,000 US dollars
- **Accrued collaboration expenses**: 105,821,000 US dollars
- **Accrued expenses**: 57,699,000 US dollars
- **Other current liabilities**: 20,257,000 US dollars
- **Accounts payable**: 4,109,000 US dollars
- **Operating lease liabilities**: 3,969,000 US dollars
- **Other long-term liabilities**: 45,469,000 US dollars
- **Non-current deferred revenue**: 31,811,000 US dollars
- **Non-current operating lease liabilities**: 3,915,000 US dollars
- **Additional paid-in capital**: 1,079,688,000 US dollars
- **Ordinary shares value - Class A ordinary shares**: 12,000 US dollars
- **Ordinary shares value - Class A1 ordinary shares**: 4,000 US dollars
- **Ordinary shares value - Class B1 ordinary shares**: 4,000 US dollars
- **Ordinary shares value - Class B ordinary shares**: 1,000 US dollars
- **Accumulated deficit**: negative 366,769,000 US dollars
- **Accumulated other comprehensive loss**: negative 2,747,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.
